Velocity Intelligence · Wound Care

Where wound care revenue actually leaks.

Wound care is the highest-stakes specialty in the revenue cycle. A single skin-substitute application can carry more revenue than a week of office visits — and a single line of missing documentation can erase it. Here's what we watch.

Reviewed Q3 2026
The Complexity

Why wound care punishes generalist billing.

Most billing companies treat a wound care visit like any other office encounter. It isn't. The dollars concentrate in a handful of codes where small details swing large amounts — debridement depth and surface area, add-on units, diabetic ulcer sequencing, and advanced therapies that carried significant revenue under the old reimbursement model and that now require entirely restructured workflows under the 2026 CMS flat-rate overhaul.

Every one of those has its own trap: add-on codes that go unbilled, status-designated codes that quietly pay $0, etiology-manifestation pairs that must be sequenced exactly, utilization limits tracked per wound across months, and prior authorizations that must be secured before the graft is ever applied. Miss one, and the revenue doesn't get flagged — it just disappears.

Where The Money Leaks

The leaks we see most often.

These aren't exotic edge cases. They're routine, and they hide in claims a practice assumes are clean. Illustrative annual exposure for a mid-sized wound care practice:

Unbilled add-on surface area

Billing the base debridement (11042) but not the add-on units (+11045, +97598) for additional surface area — billing one zone and giving away the rest.

$36K–$96Kper year

Defensive depth downcoding

Coding 97597 or 11042 when the wound went deeper — because the note was ambiguous, not because the depth wasn't there. Downcoding out of caution bleeds as much as denials do.

$100K+per year

Diabetic ulcer ICD-10 sequencing

The etiology-manifestation pair (E11.621 → L97.5xx) missing or reversed triggers an automatic CO-97 denial. It hits roughly 40% of diabetic wound claims.

$25K–$100Kexposure

The $0 status-B trap

Billing a non-selective debridement code that bundles into the office visit and reimburses nothing in that setting — work delivered, revenue never captured.

$60K–$72Kper year

Skin substitute prior-auth gaps & the 2026 rate collapse

Before 2026, a missed prior authorization on a skin substitute meant losing $3,000–$4,500 per application under the old ASP-based model. As of January 1, 2026, CMS moved to a flat ~$127/cm² rate — a ~90% cut in product reimbursement. The prior-auth risk is still real, but the bigger exposure now is practices that haven't restructured their skin-substitute workflows for the new rate. Many are billing products that no longer cover their cost.

~90%rate cut in 2026

— and that's before same-day E/M modifier errors and per-wound utilization tracking, two more we catch routinely.

The reason these bleed quietly is simple: generalist billers submit wound care the standard way and never look for them. The claims pay, the denials get written off as "just how it goes," and nobody realizes the leak is there. Knowing where the money hides is the easy part. Catching every instance, across thousands of claims, month after month — that's the work.
The 2026 Watch

What changed this year — and the twist most will miss.

Effective January 1, 2026 — CMS CY 2026 PFS Final Rule

The skin substitute rate collapse — and what most practices haven't adjusted for.

  • ~90% cut in product reimbursement. CMS moved from ASP+6% (where skin substitutes paid $200–$3,000+ per cm² depending on product) to a flat ~$127.14/cm² across all products and settings. The products didn't change. The revenue did.
  • Reclassified as "incident-to" supplies. Skin substitutes are no longer billed as biologicals. They're incident-to supplies, billed with the application procedure, with an 8-application cap per 12-week episode and a KX modifier required after application 4.
  • Only 18 products are on the covered list for DFU/VLU. CMS evaluated 66 products — 18 made the evidence threshold. 158 are no longer covered. 154 are in a 12-month "status quo" period at MAC discretion. If your practice hasn't audited its product formulary against the current covered list, you're likely billing products that will deny.
  • The twist: LCDs were withdrawn Dec 24, 2025. CMS pulled the finalized DFU/VLU coverage LCDs days before they took effect. The payment reform is fully live — the coverage criteria are in flux. Existing MAC policies govern while CMS reviews. Practices billing to the withdrawn LCD framework are exposed.
  • WISeR prior-authorization pilot also went live January 1, 2026, adding pre-service scrutiny on wound care services in the pilot states.

Source: CMS CY 2026 Physician Fee Schedule Final Rule (CMS-1832-F). CMS fact sheet ↗

Think your wound care claims are clean?

Send us your AR aging and a sample of recent denials. We'll show you exactly where the leaks are — before you owe us a dollar.

Request a Revenue Analysis